Enfortumab Vedotin Approved for Recurrent Bladder Cancer - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Enfortumab Vedotin Approved for Recurrent Bladder Cancer 01/14/2020 Enfortumab vedotin-ejfv (Padcev) has been approved for people with advanced bladder cancer. FDA granted the drug accelerated approval for cancers that have progressed despite previous treatments.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892